UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database

Pharmacoepidemiology and drug safety, 2022-06, Vol.31 (6), p.643-651

2022

Link zum Volltext

Verfügbarkeit prüfen

Treatment pathway analysis of newly diagnosed dementia patients in four electronic health record databases in Europe

Social Psychiatry and Psychiatric Epidemiology, 2021-03, Vol.56 (3), p.409-416

2021

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration‐QTc Analysis

Clinical pharmacology in drug development, 2023-01, Vol.12 (1), p.94-106

2023

Link zum Volltext

Verfügbarkeit prüfen

A Bioequivalence Comparison Between the Once‐Daily Extended‐Release Tablet and the Twice‐Daily Tablet Formulations of Deutetrabenazine at Steady State

Clinical pharmacology in drug development, 2024-03, Vol.13 (3), p.224-232

2024

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect

Clinical pharmacology in drug development, 2021-06, Vol.10 (6), p.647-659

2021

Link zum Volltext

Verfügbarkeit prüfen

The Patient-Reported Outcome (PRO) Consortium: Lessons Learned Along the Path to PRO Instrument Qualification

Therapeutic innovation & regulatory science, 2015-01, Vol.49 (1), p.132-138

2015

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia

The American journal of geriatric psychiatry, 2022-03, Vol.30 (3), p.360-371

2022

Link zum Volltext

Verfügbarkeit prüfen

On crushing of deutetrabenazine tablets

American journal of health-system pharmacy, 2021-09, Vol.78 (17), p.1551-1552

2021

Link zum Volltext

Verfügbarkeit prüfen

Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem

Nature reviews. Drug discovery, 2017-10, Vol.16 (10), p.736-736

2017

Link zum Volltext

Verfügbarkeit prüfen

P1‐324: Predicting Change in Hippocampal Volume Using MRI Features from Baseline

Alzheimer's & dementia, 2016-07, Vol.12 (7S_Part_11), p.P550-P551

2016

Link zum Volltext

Verfügbarkeit prüfen

P2‐134: Clinical characteristics of subjects with conflicting biomarkers of amyloid deposition

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_11), p.P535-P536

2015

Link zum Volltext

Verfügbarkeit prüfen

UTILITY OF THE ATN DEFINITION OF BIOMARKER STATUS IN THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P1312-P1313

2017

Link zum Volltext

Verfügbarkeit prüfen

PREDICTING CHANGE IN HIPPOCAMPAL VOLUME USING MRI FEATURES FROM BASELINE

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P550-P551

2016

Link zum Volltext

Verfügbarkeit prüfen

WHAT DETERMINES COGNITIVE FUNCTIONING IN THE OLDEST-OLD? THE EMIF-AD 90+ STUDY

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P726-P727

2019

Link zum Volltext

Verfügbarkeit prüfen

P2‐345: WHAT DETERMINES COGNITIVE FUNCTIONING IN THE OLDEST‐OLD? THE EMIF‐AD 90+ STUDY

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_14), p.P726-P727

2019

Link zum Volltext

Verfügbarkeit prüfen

Serotonin Syndrome

Movement Disorder Emergencies, p.139-169

Link zum Volltext

Verfügbarkeit prüfen

P4‐090: Multivariate prediction of change in hippocampal volume in Alzheimer's disease

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_17), p.P807-P808

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical characteristics of subjects with conflicting biomarkers of amyloid deposition

Alzheimer's & dementia, 2015-07, Vol.11 (7), p.P535-P536

2015

Link zum Volltext

Verfügbarkeit prüfen

Movement Disorder Emergencies: Diagnosis and Treatment

Frucht, Steven J.

3rd ed. 2022

Link zum Volltext

Verfügbarkeit prüfen

From big data to smart data in Alzheimer's disease. The brain health modeling initiative to foster actionable knowledge

Alzheimer's & dementia, 2016

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinically Meaningful Outcomes in Early Alzheimer Disease: A Consortia-Driven Approach to Identifying What Matters to Patients

Therapeutic innovation & regulatory science, 2017-05, Vol.51 (3), p.380-390

2017

Link zum Volltext

Verfügbarkeit prüfen

P1‐181: Operationalizing the iwg2 and nia‐aa diagnostic criteria for asymptomatic‐at‐risk for Alzheimer's disease or preclinical Alzheimer's disease

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_9), p.P414-P415

2015

Link zum Volltext

Verfügbarkeit prüfen

O1‐03‐06: Creating normative values for cognitive tests in amyloid positive and amyloid negative cognitively normal subjects

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_3), p.P131-P132

2015

Link zum Volltext

Verfügbarkeit prüfen

P2‐165: Resilience to Clinical Dementia at Old Age: The European Medical Information Framework (EMIF) 90+ Study

Alzheimer's & dementia, 2016-07, Vol.12 (7S_Part_14), p.P678-P678

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 54

Suche als RSS-Feed

Aktive Filter

KollektionEZB Electronic Journals Library

ThemaNeurosciences & Neurology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Englisch
(54)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database

Treatment pathway analysis of newly diagnosed dementia patients in four electronic health record databases in Europe

Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration‐QTc Analysis

A Bioequivalence Comparison Between the Once‐Daily Extended‐Release Tablet and the Twice‐Daily Tablet Formulations of Deutetrabenazine at Steady State

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect

The Patient-Reported Outcome (PRO) Consortium: Lessons Learned Along the Path to PRO Instrument Qualification

Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia

On crushing of deutetrabenazine tablets

F1‐02‐03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF‐AD BIOMARKER DISCOVERY STUDY

Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem

P1‐324: Predicting Change in Hippocampal Volume Using MRI Features from Baseline

P2‐134: Clinical characteristics of subjects with conflicting biomarkers of amyloid deposition

UTILITY OF THE ATN DEFINITION OF BIOMARKER STATUS IN THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE

PREDICTING CHANGE IN HIPPOCAMPAL VOLUME USING MRI FEATURES FROM BASELINE

WHAT DETERMINES COGNITIVE FUNCTIONING IN THE OLDEST-OLD? THE EMIF-AD 90+ STUDY

P2‐345: WHAT DETERMINES COGNITIVE FUNCTIONING IN THE OLDEST‐OLD? THE EMIF‐AD 90+ STUDY

Serotonin Syndrome

P4‐090: Multivariate prediction of change in hippocampal volume in Alzheimer's disease

Clinical characteristics of subjects with conflicting biomarkers of amyloid deposition

Movement Disorder Emergencies: Diagnosis and Treatment

From big data to smart data in Alzheimer's disease. The brain health modeling initiative to foster actionable knowledge

Clinically Meaningful Outcomes in Early Alzheimer Disease: A Consortia-Driven Approach to Identifying What Matters to Patients

P1‐181: Operationalizing the iwg2 and nia‐aa diagnostic criteria for asymptomatic‐at‐risk for Alzheimer's disease or preclinical Alzheimer's disease

O1‐03‐06: Creating normative values for cognitive tests in amyloid positive and amyloid negative cognitively normal subjects

P2‐165: Resilience to Clinical Dementia at Old Age: The European Medical Information Framework (EMIF) 90+ Study

Aktive Filter

Suchergebnisse filtern